Food noise is the informal name for intrusive, repetitive, low-value thoughts about food that persist between meals and often after you have eaten enough. It differs from normal hunger (a rising stomach signal that resolves with food) and from a craving (a specific desire for a specific food that resolves once addressed). Food noise is background chatter — planning the next snack while finishing lunch, mental scanning of the pantry after dinner, waking up already thinking about breakfast. The term rose in popular use after patients on GLP-1 medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) described a sudden quiet where that chatter used to be.

Do GLP-1s eliminate food noise?

For most patients, GLP-1s substantially reduce food noise but do not fully eliminate it. In the STEP-1 (Wilding 2021) and SURMOUNT-1 (Jastreboff 2022) trials, subjective appetite and food-preoccupation scales dropped sharply in the first 4 to 8 weeks and stayed lower through the maintenance dose. Neuroimaging studies (van Bloemendaal 2014; Farr 2016) show reduced activation in reward-related brain regions when patients on GLP-1s see high-calorie food cues. The honest framing is 'quieter, sometimes dramatically so,' not 'gone.' Roughly 15 to 25 percent of trial participants report only modest noise reduction even at full dose.

Why did my food noise come back after stopping Ozempic?

Because the medication was actively suppressing appetite pathways, and those pathways resume normal signaling once the drug clears. Semaglutide has a half-life of about a week, so meaningful signal returns 4 to 6 weeks after the last dose; tirzepatide is slightly faster. STEP-4 (Rubino 2021), the STEP-1 extension (Wilding 2022), and SURMOUNT-4 (Aronne 2024) all document the same pattern — hunger scales and food-preoccupation scales return to near-baseline within about 8 weeks, and most patients regain roughly two-thirds of their lost weight within a year. The return of food noise is a drug-effect wearing off, not a personal failure.

Can food noise be reduced without medication?

Yes, though the magnitude is smaller. The best-evidenced non-drug levers are adequate protein (25 to 35 g per meal), a fiber intake in the 30 to 40 g per day range with soluble fiber emphasis, 7-plus hours of regular sleep, reduced alcohol intake, and cognitive behavioral therapy (CBT) targeting eating patterns. None of these produce the sudden quiet that patients describe on semaglutide or tirzepatide, but stacked together over 6 to 12 weeks they meaningfully reduce food-related preoccupation in most people who apply them consistently.

Is food noise the same as binge eating disorder?

No. Food noise is a subclinical description of intrusive thinking about food. Binge eating disorder (BED) is a DSM-5-TR clinical diagnosis defined by recurrent episodes of eating large amounts of food with a subjective loss of control, occurring at least once a week for 3 months, and associated with distress. Many people with BED describe intense food noise, but the reverse is not true — most people with food noise do not meet BED criteria. Emotional eating is a third, overlapping pattern where eating is triggered by mood rather than hunger. First-line care differs across the three.

Does ADHD cause food noise?

ADHD is meaningfully associated with higher food-related preoccupation, hyperphagia, and reward-driven eating, though the mechanism is not fully understood. Cortese 2016 (American Journal of Psychiatry) and adjacent work point to shared dopamine-signaling pathways as one plausible driver. Stimulant medications for ADHD often reduce daytime food noise but can produce a rebound in the late afternoon or evening as the medication wears off. GLP-1s reduce food noise in ADHD populations by the same mechanism as in non-ADHD populations, though formal RCTs in ADHD cohorts are not yet published.

Does high protein reduce food noise?

Meaningfully, yes. Weigle 2005 (American Journal of Clinical Nutrition) showed that raising dietary protein from 15 to 30 percent of calories reduced daily calorie intake by about 440 kcal spontaneously, driven largely by reduced hunger and food-related thinking. Leidy 2015 (Obesity) replicated the pattern in adolescents. The practical target is 25 to 35 g of protein per meal, with breakfast being the highest-leverage meal because it anchors the appetite signal for the rest of the day. Effect size is smaller than a full-dose GLP-1 but is one of the most consistent non-drug findings.

Should I try microdosing GLP-1s just for food noise?

Not yet, on current evidence. Microdoses (semaglutide 0.25 to 0.5 mg, tirzepatide 2.5 mg) reduce food noise less consistently than approved weight-management doses, and compounded low-dose products carry meaningful safety uncertainty since the FDA lifted the semaglutide and tirzepatide shortage designations in 2024 and 2025. If food noise is your primary concern and BMI does not meet the approved indication, the honest next step is to work through the evidence-based non-drug protocol (protein, fiber, sleep, alcohol, CBT) before adding pharmacology. If food noise is severe and interfering with functioning, a clinician conversation about the underlying pattern (BED, ADHD, depression) is a higher-yield starting point than a microdose.

2026-08-07 · food noise, glp-1, appetite, cravings, semaglutide, tirzepatide, hunger hormones, behavioral, weight loss

Written by Nora Kim

Nora Kim is a WeightFAQ staff writer who translates clinical, surgical, and pharmacological weight-loss research into plain-English guidance. She covers the GLP-1 landscape — semaglutide, tirzepatide, and next-generation drugs — alongside bariatric surgery types, post-op nutrition protocols, and revision options. Her articles also address type 2 diabetes remission, cardiovascular risk, PCOS, fatty liver, night eating syndrome, sarcopenic obesity, and how common medications like antipsychotics, statins, and antidepressants affect weight. Nora writes for readers weighing serious clinical decisions and wanting a clear read on evidence, safety, cost, and realistic outcomes.

13 min read

Medically reviewed on Aug 7, 2026

Overhead flat lay of a calm wooden dining table with a glass of water, small bowl of berries, and an open book in soft afternoon light

What is food noise?: Food noise is the informal name for intrusive, repetitive, low-value thoughts about food that persist between meals and often after you have eaten enough. It differs from normal hunger (a rising stomach signal that resolves with food) and from a craving (a specific desire for a specific food that resolves once addressed). Food noise is background chatter — planning the next snack while finishing lunch, mental scanning of the pantry after dinner, waking up already thinking about breakfast. The term rose in popular use after patients on GLP-1 medications like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) described a sudden quiet where that chatter used to be.
Do GLP-1s eliminate food noise?: For most patients, GLP-1s substantially reduce food noise but do not fully eliminate it. In the STEP-1 (Wilding 2021) and SURMOUNT-1 (Jastreboff 2022) trials, subjective appetite and food-preoccupation scales dropped sharply in the first 4 to 8 weeks and stayed lower through the maintenance dose. Neuroimaging studies (van Bloemendaal 2014; Farr 2016) show reduced activation in reward-related brain regions when patients on GLP-1s see high-calorie food cues. The honest framing is 'quieter, sometimes dramatically so,' not 'gone.' Roughly 15 to 25 percent of trial participants report only modest noise reduction even at full dose.
Why did my food noise come back after stopping Ozempic?: Because the medication was actively suppressing appetite pathways, and those pathways resume normal signaling once the drug clears. Semaglutide has a half-life of about a week, so meaningful signal returns 4 to 6 weeks after the last dose; tirzepatide is slightly faster. STEP-4 (Rubino 2021), the STEP-1 extension (Wilding 2022), and SURMOUNT-4 (Aronne 2024) all document the same pattern — hunger scales and food-preoccupation scales return to near-baseline within about 8 weeks, and most patients regain roughly two-thirds of their lost weight within a year. The return of food noise is a drug-effect wearing off, not a personal failure.
Can food noise be reduced without medication?: Yes, though the magnitude is smaller. The best-evidenced non-drug levers are adequate protein (25 to 35 g per meal), a fiber intake in the 30 to 40 g per day range with soluble fiber emphasis, 7-plus hours of regular sleep, reduced alcohol intake, and cognitive behavioral therapy (CBT) targeting eating patterns. None of these produce the sudden quiet that patients describe on semaglutide or tirzepatide, but stacked together over 6 to 12 weeks they meaningfully reduce food-related preoccupation in most people who apply them consistently.
Is food noise the same as binge eating disorder?: No. Food noise is a subclinical description of intrusive thinking about food. Binge eating disorder (BED) is a DSM-5-TR clinical diagnosis defined by recurrent episodes of eating large amounts of food with a subjective loss of control, occurring at least once a week for 3 months, and associated with distress. Many people with BED describe intense food noise, but the reverse is not true — most people with food noise do not meet BED criteria. Emotional eating is a third, overlapping pattern where eating is triggered by mood rather than hunger. First-line care differs across the three.
Does ADHD cause food noise?: ADHD is meaningfully associated with higher food-related preoccupation, hyperphagia, and reward-driven eating, though the mechanism is not fully understood. Cortese 2016 (American Journal of Psychiatry) and adjacent work point to shared dopamine-signaling pathways as one plausible driver. Stimulant medications for ADHD often reduce daytime food noise but can produce a rebound in the late afternoon or evening as the medication wears off. GLP-1s reduce food noise in ADHD populations by the same mechanism as in non-ADHD populations, though formal RCTs in ADHD cohorts are not yet published.
Does high protein reduce food noise?: Meaningfully, yes. Weigle 2005 (American Journal of Clinical Nutrition) showed that raising dietary protein from 15 to 30 percent of calories reduced daily calorie intake by about 440 kcal spontaneously, driven largely by reduced hunger and food-related thinking. Leidy 2015 (Obesity) replicated the pattern in adolescents. The practical target is 25 to 35 g of protein per meal, with breakfast being the highest-leverage meal because it anchors the appetite signal for the rest of the day. Effect size is smaller than a full-dose GLP-1 but is one of the most consistent non-drug findings.
Should I try microdosing GLP-1s just for food noise?: Not yet, on current evidence. Microdoses (semaglutide 0.25 to 0.5 mg, tirzepatide 2.5 mg) reduce food noise less consistently than approved weight-management doses, and compounded low-dose products carry meaningful safety uncertainty since the FDA lifted the semaglutide and tirzepatide shortage designations in 2024 and 2025. If food noise is your primary concern and BMI does not meet the approved indication, the honest next step is to work through the evidence-based non-drug protocol (protein, fiber, sleep, alcohol, CBT) before adding pharmacology. If food noise is severe and interfering with functioning, a clinician conversation about the underlying pattern (BED, ADHD, depression) is a higher-yield starting point than a microdose.

Food Noise: What It Is, Why GLP-1s Quiet It, and What Helps If You’re Not on One

“Food noise” is not a formal clinical diagnosis. It is a patient-coined phrase that rose sharply in popular use after 2021, when adults on semaglutide and tirzepatide started describing a sudden quiet where the constant mental chatter about food used to be. The term captures something real — an intrusive, repetitive, low-value stream of thinking about food that persists between meals and even after eating enough — and it names an experience that many people with weight, disordered eating, or ADHD histories have lived with for years without a shared vocabulary for it. This guide covers what food noise is, why GLP-1 medications quiet it, what happens when the drug is stopped, and what non-drug levers actually move the signal.

What food noise actually is

Food noise is the ongoing, low-grade mental preoccupation with food that continues in the background of daily life. It is planning the next snack while finishing lunch, mentally scanning the pantry after dinner, thinking about tomorrow’s breakfast at 10 p.m., or noticing that a colleague’s granola bar has captured 20 seconds of attention it did not deserve.

The distinction from normal appetite matters:

Hunger is a rising, stomach-anchored signal driven by ghrelin, gastric distension, and blood glucose. It resolves with food and does not return for several hours.
A craving is a specific desire for a specific food (chocolate, salty crunchy, warm bread) that spikes and then either resolves when addressed or fades on its own within 20 to 30 minutes. See sugar cravings and weight loss for the 4-week craving-intensity curve on a new deficit and the 6-lever protocol that targets it.
Food noise is background chatter that persists between meals, is not tied to a specific food, and often does not resolve with eating. It is a cognitive load, not a physiological signal.

The current neuroscience framing anchors food noise on two systems working together. The hypothalamic set-point system (Berthoud 2011, Physiology & Behavior) defines a defended body weight and adjusts hunger, satiety, and energy expenditure to defend it. The mesolimbic reward system (Volkow 2013, Nature Reviews Neuroscience) assigns motivational value to food cues and drives approach behavior. When either system is dysregulated — by chronic dieting, sleep deprivation, high-palatability food environments, genetics, or comorbid ADHD — food-related thoughts intrude more frequently and are harder to dismiss. That intrusion is what patients call food noise.

Why GLP-1 medications quiet food noise

GLP-1 receptor agonists reduce food noise through four converging mechanisms that hit both the hypothalamic and reward systems at once. See our GLP-1 weight loss medications overview for the broader clinical picture; the appetite-signaling piece is what matters here.

Mechanism	Where it acts	What it changes	Key evidence
Central GLP-1 receptor activation	Hypothalamic arcuate nucleus + brainstem NTS	Raises satiety signal, lowers hunger drive at the set-point level	van Bloemendaal 2014, Diabetes; Farr 2016, Diabetologia
Reward-pathway blunting	Ventral tegmental area + nucleus accumbens	Reduces incentive salience of food cues on fMRI	van Bloemendaal 2014 fMRI; Farr 2016 semaglutide neuroimaging
Slowed gastric emptying	Stomach and upper small intestine	Prolongs post-meal fullness, feeds forward into satiety signal	FDA prescribing information for semaglutide and tirzepatide
Suppressed ghrelin release	Enteroendocrine feedback	Reduces the rising hunger signal between meals	Wilding 2022, NEJM STEP-1 extension hunger scales; Aronne 2023 SURMOUNT-1 appetite data

The reward-pathway piece is what most closely maps to the subjective “quiet” that patients describe. On fMRI, patients on semaglutide show meaningfully lower activation in reward regions when they see high-calorie food images, without matching reductions when viewing neutral objects. That selective blunting is the neuroscience correlate of “the doughnut on the counter doesn’t own my attention anymore.” The dual-agonist tirzepatide for weight loss adds GIP receptor activation on top of the GLP-1 signal, which is one of the mechanisms proposed for its larger average weight loss in SURMOUNT-5 (Aronne 2025, NEJM).

How much of the trial-reported weight loss is “food noise reduction” vs “fullness”

Both matter, and separating them is harder than it sounds. STEP-3 (Wadden 2020, JAMA) added intensive behavioral therapy on top of semaglutide 2.4 mg and reported that participants with the largest subjective-appetite reductions also lost the most weight, suggesting the appetite-signaling mechanism carries a real share of the outcome. Rubino 2022 (STEP-8, JAMA) reported the same pattern in a head-to-head trial. Le Roux 2023 real-world adherence data went further: patients who described the largest food-noise reduction were meaningfully more likely to still be on therapy at 12 months, suggesting the noise-reduction effect is what makes long-term adherence tolerable.

The honest split is roughly this: mechanical satiety (slower gastric emptying, larger meals producing lasting fullness) explains part of the reduced intake, and reward-pathway blunting (less pull toward the next snack) explains a separate part. Neither alone reproduces the trial numbers.

What happens to food noise when you stop the medication

The clearest evidence comes from three discontinuation trials. Rubino 2021 (STEP-4, JAMA) took patients who had already responded to semaglutide 2.4 mg and randomized them to continue or switch to placebo. The placebo group regained about 6.9 percent of body weight over the following 48 weeks; the continuation group lost another 7.9 percent. Wilding 2022 (STEP-1 extension) followed patients for a full year off drug and found roughly two-thirds of lost weight regained. Aronne 2024 (SURMOUNT-4, JAMA) reported the same pattern for tirzepatide: about 14 percentage points of regain over 52 weeks off drug.

Patient-reported food-noise return follows a consistent timeline. The “I forgot to eat lunch” feeling fades first, usually within 2 to 4 weeks of the last dose. Reward-cue sensitivity (the pull toward the doughnut on the counter) returns next. Full return of pre-treatment food noise happens in most patients within 4 to 8 weeks — matched to the 5-half-life clearance window of each drug. The rebound weight gain after stopping GLP-1 guide covers taper strategies and maintenance-dose options that partially mitigate this pattern.

Non-drug ways to reduce food noise

These are the highest-evidence, lowest-risk levers a person can pull without pharmacology. None reproduces the sudden GLP-1 quiet on its own; stacked together over 6 to 12 weeks they produce meaningful, if smaller, reductions in food-related preoccupation.

Lever	Typical magnitude of effect	Mechanism	Caveat
Adequate protein (25 to 35 g per meal)	Spontaneous 300 to 500 kcal per day reduction in intake; large reductions in food thoughts	Raises satiety hormones (PYY, GLP-1 endogenously); slower gastric emptying	Requires consistency; the effect appears within 1 to 2 weeks. See Weigle 2005 AJCN; Leidy 2015 Obesity
Fiber (30 to 40 g per day, soluble emphasis)	100 to 250 kcal per day reduction; smaller inter-meal preoccupation	Fermentation-driven satiety hormones; slower glucose absorption	Ramp gradually to avoid GI distress. See Slavin 2005 Nutrition; Wanders 2011 Obesity Reviews
Regular sleep (7-plus hours, consistent timing)	Reduced ghrelin, higher leptin, lower next-day hunger scores	Sleep debt shifts the hunger-satiety hormone balance	The single biggest lever for many people. See Spiegel 2004 Ann Intern Med; Nedeltcheva 2010 Ann Intern Med
Alcohol reduction	Fewer disinhibited eating episodes; less next-day hunger	Alcohol suppresses leptin and disinhibits pre-frontal control	Effect scales with baseline intake. See Yeomans 2010 Physiology & Behavior
CBT for eating (CBT-E or self-guided workbook)	Meaningful reduction in food preoccupation over 8 to 16 weeks	Modifies thought-behavior loops around eating	Requires consistent practice; combining with a clinician accelerates. See Cooper 2010 Behav Res Ther; Butryn 2011 Med Clin North Am

The practical version of the protein lever is straightforward: front-load it. See our high-protein breakfast ideas for meal templates that hit the 25 to 35 g target. For the CBT lever, behavioral therapy for weight loss covers how to find a therapist trained in eating-focused CBT and what a course typically looks like.

A note on hunger-cue calibration for active GLP-1 users: any framework that asks you to trust internal hunger and fullness signals — including the Tribole and Resch intuitive eating framework’s Principles 2 (Honor Your Hunger) and 6 (Feel Your Fullness) — assumes those signals accurately reflect biological need. On semaglutide or tirzepatide, that assumption breaks down; the medication pharmacologically dampens the cues themselves. Many patients benefit from the anti-diet-culture and food-neutrality pieces of intuitive eating (Principles 1, 3, 4, and 10) while using structured protein and meal-timing targets — not hunger cues — to prevent under-eating on medication.

Food noise and ADHD

ADHD and elevated food noise co-occur at rates well above chance. Yolton 2014 (Pediatrics) documented the ADHD-obesity association across adolescence, and Cortese 2016 (American Journal of Psychiatry) reviewed the shared dopamine-signaling pathways that plausibly explain the overlap. In adults, ADHD is associated with higher rates of binge eating, night eating, and reward-driven eating patterns — all of which map onto the food-noise construct.

Stimulant medications for ADHD (methylphenidate, mixed amphetamine salts, lisdexamfetamine) reduce daytime food noise for most patients through direct appetite suppression. The clinically important pattern is the evening rebound: as the medication wears off, appetite returns disproportionately, often driving a compressed evening eating window with higher calorie intake than the daytime suppression would have predicted. Patients frequently describe this as “I forgot to eat all day and then couldn’t stop at 8 p.m.” The ADHD and weight loss guide covers the medication timing and behavioral scaffolding that reduce the rebound pattern.

Food noise vs binge eating disorder vs emotional eating

These three constructs overlap but are not interchangeable, and the first-line care pathway differs across them.

Construct	Definition	Typical trigger	DSM-5-TR status	First-line approach
Food noise	Intrusive, repetitive, low-value thoughts about food between meals	Cue exposure, sleep debt, hunger physiology	Not a diagnosis	Protein, fiber, sleep, CBT skills; GLP-1 if BMI qualifies
Binge eating disorder	Recurrent episodes of large-quantity eating with loss of control, at least weekly for 3 months, associated distress	Emotional dysregulation, restriction-driven rebound	Formal diagnosis (APA DSM-5-TR)	CBT-E; lisdexamfetamine; specialist involvement
Emotional eating	Eating triggered by mood (stress, sadness, boredom) rather than hunger	Emotional state	Subclinical pattern	Emotion-regulation skills; CBT; see emotional eating and weight loss

Grilo 2020 (NEJM) is the current best clinical summary of BED. The practical point is that severe, distressing food noise that includes loss-of-control eating episodes deserves a screening conversation with a clinician rather than a self-directed fix — the underlying pattern may meet BED criteria and warrant the specific CBT-E plus lisdexamfetamine pathway rather than the general non-drug protocol above.

Food noise on GLP-1 microdoses and compounded formulations

The interest in low-dose or “microdose” GLP-1s for food noise alone has grown as the terminology has spread. The honest evidence picture is mixed. Aroda 2024 (Diabetes Care) reported that lower doses of semaglutide produce smaller and less consistent appetite reductions than the approved 2.4 mg weight-management dose. Some patients report meaningful food-noise reduction at 0.25 or 0.5 mg semaglutide; others report almost none.

Compounded semaglutide and tirzepatide became widely available during the 2022 to 2024 shortage window but carry meaningful safety uncertainty since the FDA lifted the shortage designations in 2024 and 2025. FDA safety communications have flagged dosing-error hospitalizations, sterility failures, and unapproved salt forms across the compounded market. Our GLP-1 microdosing guide covers the current legal and safety landscape in more detail.

The straightforward guidance: microdoses do not reliably deliver the food-noise reduction that approved doses do, and the compounded route adds safety uncertainty on top of that. If food noise is the primary target and BMI does not qualify for on-label GLP-1 use, the non-drug protocol below is a higher-value starting point than a microdose.

A 30-day non-drug food-noise-reduction protocol

This is a structured, testable sequence that layers the highest-evidence non-drug levers over 4 weeks. Track a simple 0-to-10 daily food-noise score at the same time each morning; the goal is a 2- to 4-point reduction by day 30.

Week	Focus	Daily targets	What to track
1	Protein anchor + sleep audit	25 to 35 g protein per meal, breakfast within 90 minutes of waking; 7+ hours in bed with consistent timing	Morning food-noise score (0 to 10); protein g logged
2	Fiber + alcohol audit	30 to 40 g fiber per day (add 5 g every 2 to 3 days to avoid GI distress); alcohol intake logged; a 1-week alcohol-free trial if intake is above 7 drinks per week	Morning food-noise score; fiber g; drinks per day
3	CBT thought record + mindful eating	Daily 5-minute thought record on the highest-noise meal; one meal per day eaten without screens or scrolling	Number of intrusive food thoughts noticed; unhurried meals per day
4	Review + optional clinician conversation	Continue all prior habits; review 30-day score trend; if score has not improved by 2+ points, book a clinician conversation	Trend line day 1 to day 30; decision point at day 30

The mindful-eating piece specifically — slowing down, single-tasking meals, and noticing satiety cues in real time — has replicable evidence for reducing food preoccupation and post-meal grazing. See our mindful eating for weight loss guide for the specific practices and how to build the habit. The behavioral scaffolding as a whole is covered in behavioral therapy for weight loss — a self-guided 30-day protocol is a reasonable first pass, but a therapist trained in eating-focused CBT is the higher-yield route if the pattern is entrenched.

When to talk to a clinician

The 30-day protocol is a reasonable self-guided first pass for garden-variety food noise. Escalate to a clinician conversation when any of the following is true:

Food noise is interfering with work, sleep, relationships, or daily functioning
Noise is escalating without a matching new stressor
Loss-of-control eating episodes are recurrent (a BED screen is warranted)
Co-occurring depression, restrictive eating, or a history of an eating disorder
You are considering a GLP-1 primarily for food noise rather than weight
The 30-day protocol produced no measurable reduction

None of these are emergencies. All of them are reasons to route the question through a primary care physician, an obesity-medicine specialist, or a mental-health clinician trained in eating-focused CBT rather than continuing to self-manage.

Sources at a glance

Berthoud HR. Metabolic and hedonic drives in the neural control of appetite. Physiology & Behavior, 2011.
Volkow ND et al. The addictive dimensionality of obesity. Nature Reviews Neuroscience, 2013.
van Bloemendaal L et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas. Diabetes, 2014.
Farr OM et al. GLP-1 receptors exist in the parietal cortex, hypothalamus, and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity. Diabetologia, 2016.
Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP-1). NEJM, 2021.
Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance (STEP-4). JAMA, 2021.
Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy (STEP-3). JAMA, 2020.
Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP-1 extension). NEJM, 2022.
Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM, 2022.
Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA, 2024.
Rubino DM et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight (STEP-8). JAMA, 2022.
Weigle DS et al. A high-protein diet induces sustained reductions in appetite, ad libitum caloric intake, and body weight. American Journal of Clinical Nutrition, 2005.
Leidy HJ et al. The role of protein in weight loss and maintenance. Obesity, 2015.
Spiegel K et al. Brief communication: sleep curtailment in healthy young men is associated with decreased leptin levels, elevated ghrelin levels, and increased hunger and appetite. Annals of Internal Medicine, 2004.
Nedeltcheva AV et al. Insufficient sleep undermines dietary efforts to reduce adiposity. Annals of Internal Medicine, 2010.
Yeomans MR. Alcohol, appetite and energy balance: is alcohol intake a risk factor for obesity? Physiology & Behavior, 2010.
Cooper Z et al. Testing a new cognitive behavioural treatment for obesity: a randomized controlled trial with three-year follow-up. Behaviour Research and Therapy, 2010.
Butryn ML et al. Behavioral treatment of obesity. Medical Clinics of North America, 2011.
Cortese S et al. Association between ADHD and obesity: a systematic review and meta-analysis. American Journal of Psychiatry, 2016.
Yolton K et al. ADHD and childhood obesity. Pediatrics, 2014.
Grilo CM. Treatment of binge eating disorder. NEJM, 2020.
APA. Diagnostic and Statistical Manual of Mental Disorders, 5th ed., Text Revision (DSM-5-TR), 2022.
Aronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). NEJM, 2025.
Aroda VR et al. Efficacy and safety of low-dose semaglutide (Aroda 2024). Diabetes Care, 2024.
FDA compounding-safety communications on semaglutide and tirzepatide, 2024-2025.

Nora Kim

Medical weight loss writer

Nora Kim covers medical and surgical weight loss options, GLP-1 therapies, and evidence-based supplements. She focuses on explaining clinical research, safety considerations, and practical next steps so readers can discuss treatment choices with their care teams.